Discovery, development and application of drugs targeting BCL-2 pro-survival proteins in cancer
© 2021 The Author(s)..
The discovery of a new class of small molecule compounds that target the BCL-2 family of anti-apoptotic proteins is one of the great success stories of basic science leading to translational outcomes in the last 30 years. The eponymous BCL-2 protein was identified over 30 years ago due to its association with cancer. However, it was the unveiling of the biochemistry and structural biology behind it and its close relatives' mechanism(s)-of-action that provided the inspiration for what are now known as 'BH3-mimetics', the first clinically approved drugs designed to specifically inhibit protein-protein interactions. Herein, we chart the history of how these drugs were discovered, their evolution and application in cancer treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Biochemical Society transactions - 49(2021), 5 vom: 01. Nov., Seite 2381-2395 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Erinna F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 16.02.2022 Date Revised 16.02.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1042/BST20210749 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33057924X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33057924X | ||
| 003 | DE-627 | ||
| 005 | 20231225211604.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1042/BST20210749 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1101.xml |
| 035 | |a (DE-627)NLM33057924X | ||
| 035 | |a (NLM)34515749 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Erinna F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Discovery, development and application of drugs targeting BCL-2 pro-survival proteins in cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2022 | ||
| 500 | |a Date Revised 16.02.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Author(s). | ||
| 520 | |a The discovery of a new class of small molecule compounds that target the BCL-2 family of anti-apoptotic proteins is one of the great success stories of basic science leading to translational outcomes in the last 30 years. The eponymous BCL-2 protein was identified over 30 years ago due to its association with cancer. However, it was the unveiling of the biochemistry and structural biology behind it and its close relatives' mechanism(s)-of-action that provided the inspiration for what are now known as 'BH3-mimetics', the first clinically approved drugs designed to specifically inhibit protein-protein interactions. Herein, we chart the history of how these drugs were discovered, their evolution and application in cancer treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a BCL-2 | |
| 650 | 4 | |a BCL-XL | |
| 650 | 4 | |a BH3-mimetics | |
| 650 | 4 | |a MCL-1 | |
| 650 | 4 | |a apoptosis | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a BCL2 protein, human |2 NLM | |
| 650 | 7 | |a Ligands |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-bcl-2 |2 NLM | |
| 700 | 1 | |a Fairlie, W Douglas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biochemical Society transactions |d 1976 |g 49(2021), 5 vom: 01. Nov., Seite 2381-2395 |w (DE-627)NLM000003379 |x 1470-8752 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2021 |g number:5 |g day:01 |g month:11 |g pages:2381-2395 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1042/BST20210749 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2021 |e 5 |b 01 |c 11 |h 2381-2395 | ||